Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 27:12:957792.
doi: 10.3389/fonc.2022.957792. eCollection 2022.

Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Feiyu Li  1 , Yong Jiang  1 , Liyong Jiang  1 , Qingbin Li  2 , Xiangyu Yan  1 , Songhan Huang  1 , Ji Chen  2 , Shuai Yuan  2 , Yingda Fu  1 , Jun Liu  1
Affiliations
Review

Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Feiyu Li et al. Front Oncol. .

Abstract

Background: The purpose of this meta-analysis was to evaluate the efficacy of lymph node dissection in patients with intrahepatic cholangiocarcinoma (ICC).

Methods: The literature from January 2009 to December 2021 was searched to determine the comparative study of lymph node dissection and non-lymph node dissection in patients with ICC.

Results: Seventeen studies were included in the analysis. There were no significant differences in 1-, 3-, and 5-year overall survival (OR = 0.80, p = 0.10; OR = 0.93, p = 0.71; OR = 0.80, p = 0.21) and 1-, 3-, and 5-year disease-free survival (OR = 0.89, p = 0.73; OR = 0.92, p = 0.81; OR = 0.85, p = 0.62).

Conclusions: Lymph node dissection does not seem to have a positive effect on the overall survival and disease-free survival.

Keywords: disease-free survival; intrahepatic cholangiocarcinoma; lymph node; overall survival; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Diagram of literature search and study selection.
Figure 2
Figure 2
Forest plot comparing overall survival in LND+ and LND− groups. (A) 1-year OS; (B) 3-year OS; (C) 5-year OS.
Figure 3
Figure 3
Forest plot comparing disease-free survival in LND+ and LND− groups. (A) 1-year DFS; (B) 3-year DFS; (C) 5-year DFS.
See this image and copyright information in PMC

References

    1. Gupta A, Dixon E. Epidemiology and risk factors: Intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 6(2):101–4. doi: 10.21037/hbsn.2017.01.02 - DOI - PMC - PubMed
    1. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2013) 11(1):13–21.e1. doi: 10.1016/j.cgh.2012.09.009 - DOI - PMC - PubMed
    1. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol (2014) 60(6):1268–89. doi: 10.1016/j.jhep.2014.01.021 - DOI - PubMed
    1. Ricci AD, Brandi G, AJEooid R. Durvalumab: An investigational anti-Pd-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs (2021) 30-1/6:343–350. doi: 10.1080/13543784.2021.1897102 - DOI - PubMed
    1. Rizzo A, Ricci AD, Brandi GJCT, Communications R. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun (2021); 27:100337. doi: 10.1016/j.ctarc.2021.100337 - DOI - PubMed

LinkOut - more resources